Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $370.86

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $370.86.

A number of equities analysts recently weighed in on the stock. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st.

United Therapeutics Price Performance

United Therapeutics stock opened at $352.84 on Monday. The firm has a 50-day moving average of $370.07 and a 200-day moving average of $349.90. The company has a market cap of $15.75 billion, a price-to-earnings ratio of 15.50, a P/E/G ratio of 1.05 and a beta of 0.55. United Therapeutics has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics will post 25.22 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 150,216 shares of company stock valued at $56,269,811 in the last quarter. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Tri Locum Partners LP bought a new position in shares of United Therapeutics in the 2nd quarter valued at $15,959,000. Franklin Resources Inc. boosted its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after buying an additional 123,929 shares in the last quarter. Bridgewater Associates LP raised its stake in United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after acquiring an additional 49,003 shares in the last quarter. Glenmede Trust Co. NA raised its stake in United Therapeutics by 6.4% during the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after acquiring an additional 4,145 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after purchasing an additional 22,978 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.